Rxgen, Inc.

NEW HAVEN, CT 06511

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $4.48MM
Active Awards 1 valued at $208K
First Award Date 08/01/04
Most Recent Award Date 09/06/17

Key Personnel

Last Name Name Awards Contact
Lawrence Matthew S Lawrence 9
Gullans Steven R Gullans 1
WAKEMAN DUSTIN ROBERT WAKEMAN 1

11 Awards Won

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-180
Budget: 09/06/17 - 09/05/18

PROJECT SUMMARY Patients with Alzheimer's disease (AD) suffer a progressive loss of memory and cognitive ability, and eventual loss of basic bodily functions and death. Currently 11% of Americans over 65 have AD and its incidence and toll on the healthcare system continues to rise with significant societal impact. There are no treatments for AD ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/30/13 - 08/31/14

Optic nerve and retinal diseases profoundly impact quality of life and overall health care burden. Demetrios Vavvas and colleagues at the Mass Eye and Ear Infirmary (MEEI) have revealed a critical redundant role of mediators of both apoptosis and necrosis in cell death in the neuroretina and optic nerve in multiple ophthalmic disease models, sup...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): Heart disease remains the primary cause of morbidity and mortality in the industrialized world and continues to incur costs estimated at $30 billion per year, despite detailed understanding of the mechanisms governing cardiac function and contractility. MicroRNAs (miRNAs), a recently discovered family of tiny...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 06/01/09 - 05/31/10

DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CNS), as well as a considerable hurdle to the delivery of therapeutic agents. A technology allowing safe, targeted, reversible opening of the BBB would poten...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 06/15/08 - 05/31/09

DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CNS), as well as a considerable hurdle to the delivery of therapeutic agents. A technology allowing safe, targeted, reversible opening of the BBB would poten...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/06 - 07/31/07

DESCRIPTION (provided by applicant): SBIR Phase I Research: This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical drug development therefore is the early identifica...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/06 - 07/31/07

DESCRIPTION (provided by applicant): SBIR Phase I Research: This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical drug development therefore is the early identifica...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/02/06 - 03/31/07

DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CMS), and a considerable hurdle to the delivery of therapeutic agents. A technology allowing safe, targeted, reversible opening of the BBB would potentially ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/05 - 07/31/06

DESCRIPTION (provided by applicant): SBIR Phase I Research: This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical drug development therefore is the early identifica...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/04 - 08/14/06

DESCRIPTION (provided by applicant): Parkinson's disease is a prevalent and devastating neurodegenerative condition of unknown etiology. One prominent hypothesis holds that the selective loss of the nigrostriatal dopaminergic neurons characteristic of the disease results from damage from environmental neurotoxins in genetically vulnerable indiv...

Load More